BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

500 related articles for article (PubMed ID: 32365922)

  • 1. Co-Transplantation of Bone Marrow-MSCs and Myogenic Stem/Progenitor Cells from Adult Donors Improves Muscle Function of Patients with Duchenne Muscular Dystrophy.
    Klimczak A; Zimna A; Malcher A; Kozlowska U; Futoma K; Czarnota J; Kemnitz P; Bryl A; Kurpisz M
    Cells; 2020 Apr; 9(5):. PubMed ID: 32365922
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transplantation of Dystrophin Expressing Chimeric Human Cells of Myoblast/Mesenchymal Stem Cell Origin Improves Function in Duchenne Muscular Dystrophy Model.
    Siemionow M; Szilagyi E; Cwykiel J; Domaszewska-Szostek A; Heydemann A; Garcia-Martinez J; Siemionow K
    Stem Cells Dev; 2021 Feb; 30(4):190-202. PubMed ID: 33349121
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alterations in Notch signalling in skeletal muscles from mdx and dko dystrophic mice and patients with Duchenne muscular dystrophy.
    Church JE; Trieu J; Chee A; Naim T; Gehrig SM; Lamon S; Angelini C; Russell AP; Lynch GS
    Exp Physiol; 2014 Apr; 99(4):675-87. PubMed ID: 24443351
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Placenta-derived mesenchymal stromal cells and their exosomes exert therapeutic effects in Duchenne muscular dystrophy.
    Bier A; Berenstein P; Kronfeld N; Morgoulis D; Ziv-Av A; Goldstein H; Kazimirsky G; Cazacu S; Meir R; Popovtzer R; Dori A; Brodie C
    Biomaterials; 2018 Aug; 174():67-78. PubMed ID: 29783118
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Partial Ablation of Non-Myogenic Progenitor Cells as a Therapeutic Approach to Duchenne Muscular Dystrophy.
    Gao Z; Lu A; Daquinag AC; Yu Y; Huard M; Tseng C; Gao X; Huard J; Kolonin MG
    Biomolecules; 2021 Oct; 11(10):. PubMed ID: 34680151
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mesenchymal stem cells derived from human induced pluripotent stem cells improve the engraftment of myogenic cells by secreting urokinase-type plasminogen activator receptor (uPAR).
    Elhussieny A; Nogami K; Sakai-Takemura F; Maruyama Y; Takemura N; Soliman WT; Takeda S; Miyagoe-Suzuki Y
    Stem Cell Res Ther; 2021 Oct; 12(1):532. PubMed ID: 34627382
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Beneficial role of adipose-derived mesenchymal stem cells from microfragmented fat in a murine model of duchenne muscular dystrophy.
    Bouglé A; Rocheteau P; Briand D; Hardy D; Verdonk F; Tremolada C; Hivelin M; Chrétien F
    Muscle Nerve; 2019 Sep; 60(3):328-335. PubMed ID: 31228273
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human Umbilical Cord Mesenchymal Stem Cells in the Treatment of Duchenne Muscular Dystrophy: Safety and Feasibility Study in India.
    Rajput BS; Chakrabarti SK; Dongare VS; Ramirez CM; Deb KD
    J Stem Cells; 2015; 10(2):141-56. PubMed ID: 27125141
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of Motor Unit Potentials Duration as the Biomarker of DT-DEC01 Cell Therapy Efficacy in Duchenne Muscular Dystrophy Patients up to 12 Months After Systemic-Intraosseous Administration.
    Niezgoda A; Biegański G; Wachowiak J; Czarnota J; Siemionow K; Heydemann A; Ziemiecka A; Sikorska MH; Bożyk K; Siemionow M
    Arch Immunol Ther Exp (Warsz); 2023 Nov; 71(1):24. PubMed ID: 37999748
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dystrophin-deficient pigs provide new insights into the hierarchy of physiological derangements of dystrophic muscle.
    Klymiuk N; Blutke A; Graf A; Krause S; Burkhardt K; Wuensch A; Krebs S; Kessler B; Zakhartchenko V; Kurome M; Kemter E; Nagashima H; Schoser B; Herbach N; Blum H; Wanke R; Aartsma-Rus A; Thirion C; Lochmüller H; Walter MC; Wolf E
    Hum Mol Genet; 2013 Nov; 22(21):4368-82. PubMed ID: 23784375
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term persistence of donor nuclei in a Duchenne muscular dystrophy patient receiving bone marrow transplantation.
    Gussoni E; Bennett RR; Muskiewicz KR; Meyerrose T; Nolta JA; Gilgoff I; Stein J; Chan YM; Lidov HG; Bönnemann CG; Von Moers A; Morris GE; Den Dunnen JT; Chamberlain JS; Kunkel LM; Weinberg K
    J Clin Invest; 2002 Sep; 110(6):807-14. PubMed ID: 12235112
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Therapy of Duchenne muscular dystrophy with umbilical cord blood stem cell transplantation].
    Zhang C; Feng HY; Huang SL; Fang JP; Xiao LL; Yao XL; Chen C; Ye X; Zeng Y; Lu XL; Wen JM; Zhang WX; Li Z; Feng SW; Xu HG; Huang K; Zhou DH; Chen W; Xie YM; Xi J; Zhang M; Li Y; Liu Y
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2005 Aug; 22(4):399-405. PubMed ID: 16086277
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human mesenchymal stem cells ectopically expressing full-length dystrophin can complement Duchenne muscular dystrophy myotubes by cell fusion.
    Gonçalves MA; de Vries AA; Holkers M; van de Watering MJ; van der Velde I; van Nierop GP; Valerio D; Knaän-Shanzer S
    Hum Mol Genet; 2006 Jan; 15(2):213-21. PubMed ID: 16321987
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-Fibrotic Effect of Human Wharton's Jelly-Derived Mesenchymal Stem Cells on Skeletal Muscle Cells, Mediated by Secretion of MMP-1.
    Choi A; Park SE; Jeong JB; Choi SJ; Oh SY; Ryu GH; Lee J; Jeon HB; Chang JW
    Int J Mol Sci; 2020 Aug; 21(17):. PubMed ID: 32872523
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cellular senescence-mediated exacerbation of Duchenne muscular dystrophy.
    Sugihara H; Teramoto N; Nakamura K; Shiga T; Shirakawa T; Matsuo M; Ogasawara M; Nishino I; Matsuwaki T; Nishihara M; Yamanouchi K
    Sci Rep; 2020 Oct; 10(1):16385. PubMed ID: 33046751
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activation of non-myogenic mesenchymal stem cells during the disease progression in dystrophic dystrophin/utrophin knockout mice.
    Sohn J; Lu A; Tang Y; Wang B; Huard J
    Hum Mol Genet; 2015 Jul; 24(13):3814-29. PubMed ID: 25859011
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhanced cell survival and therapeutic benefits of IL-10-expressing multipotent mesenchymal stromal cells for muscular dystrophy.
    Nitahara-Kasahara Y; Kuraoka M; Oda Y; Hayashita-Kinoh H; Takeda S; Okada T
    Stem Cell Res Ther; 2021 Feb; 12(1):105. PubMed ID: 33541428
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human multipotent adipose-derived stem cells restore dystrophin expression of Duchenne skeletal-muscle cells in vitro.
    Vieira NM; Brandalise V; Zucconi E; Jazedje T; Secco M; Nunes VA; Strauss BE; Vainzof M; Zatz M
    Biol Cell; 2008 Apr; 100(4):231-41. PubMed ID: 17997718
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Skeletal Muscle Differentiation on a Chip Shows Human Donor Mesoangioblasts' Efficiency in Restoring Dystrophin in a Duchenne Muscular Dystrophy Model.
    Serena E; Zatti S; Zoso A; Lo Verso F; Tedesco FS; Cossu G; Elvassore N
    Stem Cells Transl Med; 2016 Dec; 5(12):1676-1683. PubMed ID: 27502519
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term engraftment of multipotent mesenchymal stromal cells that differentiate to form myogenic cells in dogs with Duchenne muscular dystrophy.
    Nitahara-Kasahara Y; Hayashita-Kinoh H; Ohshima-Hosoyama S; Okada H; Wada-Maeda M; Nakamura A; Okada T; Takeda S
    Mol Ther; 2012 Jan; 20(1):168-77. PubMed ID: 21934652
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.